PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33889509-0	2021	Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance.	Metformin	18-27	epidermal growth factor receptor	Homo sapiens	53-57	
33889509-0	2021	Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer-an option for overcoming EGFR-TKI resistance.	Metformin	18-27	epidermal growth factor receptor	Homo sapiens	89-93	
33889509-7	2021	Metformin can also augment apoptosis effect of these TKI-resistant cells to EGFR-TKIs.	Metformin	0-9	epidermal growth factor receptor	Homo sapiens	76-80	
33889509-11	2021	Further analysis revealed that metformin obviously prolonged the median PFS2 of osimertinib treatment among patients who progressed to prior line EGFR-TKIs due to secondary EGFR T790M mutation (cohort B).	Metformin	31-40	epidermal growth factor receptor	Homo sapiens	146-150	
33889509-11	2021	Further analysis revealed that metformin obviously prolonged the median PFS2 of osimertinib treatment among patients who progressed to prior line EGFR-TKIs due to secondary EGFR T790M mutation (cohort B).	Metformin	31-40	epidermal growth factor receptor	Homo sapiens	173-177	
33889509-12	2021	Conclusions: Our study suggest that concurrent use of metformin could be beneficial to EGFR-mutant NSCLC patients treated with either first-line EGFR-TKIs or second-line osimertinib.	Metformin	54-63	epidermal growth factor receptor	Homo sapiens	87-91	
33889509-12	2021	Conclusions: Our study suggest that concurrent use of metformin could be beneficial to EGFR-mutant NSCLC patients treated with either first-line EGFR-TKIs or second-line osimertinib.	Metformin	54-63	epidermal growth factor receptor	Homo sapiens	145-149